Max S. Wicha, M.D.
Dr. Wicha also serves as the distinguished professor of oncology, professor of internal medicine and is nationally known for his research in the field of breast oncology, particularly the study of how breast cancer cells grow and metastasize. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor.
Since then, Dr. Wicha has become one of the leading experts on cancer stem cells, with his continued work on breast cancer stem cells. He has also led efforts within the UMCCC to expand these findings into other tumor types. U-M researchers were first to discover stem cells in pancreatic and head and neck cancers and are focusing on cancer stem cells in virtually every cancer type, including colon, lung and thyroid tumors.
Dr. Wicha is also active as a clinician, specializing in the treatment of breast cancer patients. He has served as chairman of the board of the Association of American Cancer Institutes and as past chairman for the National Cancer Institute's Cancer Center Support Review Committee.
Dr. Wicha joined the University of Michigan Medical Center in 1980. From 1984 to 1993, he served as chief in the Division of Hematology/Oncology in the Department of Internal Medicine. Dr. Wicha received his medical degree from Stanford University and trained in internal medicine at the University of Chicago. He then went on to the National Cancer Institute, where he trained in clinical oncology and cancer biology.
Alfred E. Chang, M.D.
Chief of Surgical Oncology
Dr. Chang has special expertise in the treatment of melanomas, breast cancers and gastrointestinal cancers. He was formerly the director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center and is currently the director of the Gastrointestinal Oncology Research Program at the Center. Dr. Chang is on numerous editorial boards of journals dealing with clinical research, surgical oncology and tumor immunology.
Prior to coming to the University of Michigan Health System, he was a senior investigator in the Surgery Branch of the National Cancer Institute. Dr. Chang received his medical degree from Harvard Medical School and completed his surgical residency at Duke University and the University of Pennsylvania, with an intervening surgical oncology fellowship at the National Cancer Institute.
Kathleen Cooney, M.D.
Frances and Victor Ginsberg Professor of Hematology/Oncology
Professor of Internal Medicine and Urology
Chief, Division of Hematology/Oncology
Deputy Director for Clinical Services, UMCCC
Dr. Kathleen Cooney is a Professor of Internal Medicine and Urology at the University of Michigan Medical School. In January 2009, she was appointed Chief of the Division of Hematology/Oncology in the Department of Internal Medicine at the University of Michigan Medical School and Associate Director for Faculty Affairs for the University of Michigan Comprehensive Cancer Center (UMCCC). Since April 2007, Dr. Cooney has served as the Interim Chief of the Division of Hematology/Oncology. In this role she was instrumental in the development of a junior faculty mentoring program, the continued recruitment of key physician scientist and clinician scholar faculty, and the enhancement of clinical operations.
Dr. Cooney is a highly respected physician scientist who, in addition to establishing an international reputation in the field of prostate cancer research, has contributed extensively to the clinical, teaching and service missions of the University of Michigan. Her work on the identification and characterization of genetic factors which cause or influence the development of prostate cancer has resulted in numerous significant contributions to the field. Dr. Cooney's scientific productivity is reflected in her bibliography which includes 87 peer-reviewed articles, 50 of which have been published in the past 5 years. She has a large portfolio of intra and extramural grants - she serves as Principal Investigator or Co-Investigator on numerous NIH awards, including serving as Co-Director of the NCI SPORE in prostate cancer grant. Dr. Cooney's international stature is also evidenced in her service on major editorial boards (including Clinical Cancer Research) and NIH advisory panels, extensive extramural invited presentations, and service on national and international professional and scientific committees, including the Steering Committee of the International Consortium for Prostate Cancer Genetics (ICPCG).
In addition to her scholarly efforts, Dr. Cooney is also a committed teacher and mentor. She is involved in the training of students at all levels, both in the laboratory and the clinic, and through numerous didactic presentations. Dr. Cooney also remains a dedicated clinician, serving as a staff physician at the Ann Arbor Veteran's Affairs Medical Center (VAMC) and the UMCCC, and as Service Chief for the Division of Hematology/Oncology. Her clinical practice is focused on caring for patients with bladder and/or prostate cancer as part of the Multidisciplinary Urologic Oncology Clinic at the UMCCC.
Eric R. Fearon, M.D., Ph.D.
Deputy Director and Associate Director for Basic Science Research
Eric R. Fearon, M.D., Ph.D., associate director for basic science research and Maisel professor of oncology, is responsible for coordinating studies of the mechanisms underlying cancer development, as well as the translation of laboratory observations to clinical applications in the diagnosis and management of cancer.
A nationally recognized expert in the field of cancer genetics, Dr. Fearon also serves as co-director of the Cancer Centers Genetics Research Program, which focuses on identifying the genetic alterations and gene expression changes that underlie the development of cancer. In addition, the Program strives to apply the emerging information to improve risk assessment, prevention, pre-symptomatic diagnosis, early detection, and therapy of cancer.
Dr. Fearon's research focuses on the nature and role of genetic alterations and gene expression changes in colorectal and other cancers of the gastrointestinal tract. He holds a primary appointment in the Department of Internal Medicine, Division of Medical Genetics, and joint appointments in the departments of Human Genetics and Pathology at the University of Michigan. Dr. Fearon is an editorial board member or editor for a number of scientific journals.
Prior to joining the faculty at the University of Michigan in 1995, Dr. Fearon was an assistant professor at Yale University School of Medicine. He received his medical and research degrees and was a postdoctoral fellow at Johns Hopkins University in Baltimore.
Maha H. Hussain, M.D.,
Associate Director of Clinical Research
Maha Hussain, M.D., is a professor of Internal Medicine and Urology. She is nationally and internationally recognized in the field of oncology, specifically in genitourinary cancer. She serves as co-leader of the Cancer Center's Urologic Oncology Program, and her research focuses on new therapies for prostate cancer and bladder cancer. In addition, she treats patients with genitourinary cancers.
Dr. Hussain has held numerous leadership positions in clinical research, including as an adviser and chair of the U.S. Food and Drug Administration's Oncology Drug Advisory Committee, a leader of the Southwest Oncology Group Genitourinary Committee and chair of the American Society of Clinical Oncology Education Committee. In addition, Dr. Hussain chaired the University of Michigan Medical School's Dean's Advisory Council on Clinical Research.
Dr. Hussain is a fellow with the American College of Physicians, completed a fellowship in hematology and oncology at Wayne State University and is an editorial board member or editor for a number of scientific journals.
Prior to joining the faculty at the University of Michigan in 2002, Dr. Hussain was an assistant professor at Wayne State University and a staff physician at the VA Medical Center in Detroit. She received her medical degree from Baghdad University School of Medicine.
Theodore S. Lawrence, M.D., Ph.D.
Chair, Radiation Oncology
Theodore S. Lawrence, M.D., Ph.D., Isadore Lampe professor of radiation oncology, is the chair of the Department of Radiation Oncology and a professor in the Department of Environmental Health, School of Public Health. He is co-chair of the Radiation Sciences Program and head of the Experimental Irradiation Core of the Cancer Center. On a national level, he is the chair of the National Cancer Institute Board of Scientific Councilors and a member of the Institute of Medicine. He is an editor of The Cancer Journal: Journal of the Principles and Practice of Oncology. Dr. Lawrence is a past president and chairman of the board of the American Society for Therapeutic Radiology and Oncology (ASTRO), the chief professional society for radiation oncology, and a past member of the Board of Directors of ASCO.
Dr. Lawrence's interests in the laboratory are focused on chemotherapeutic and molecularly targeted radiosensitizer. His clinical research combines these laboratory studies with conformal radiation guided by metabolic and functional imaging for the treatment of patients with gastrointestinal and central nervous system malignancies.
Dr. Lawrence joined the faculty of the University of Michigan in 1987, following a fellowship in medical oncology and a residency in radiation oncology at the National Cancer Institute. He received his research degree in cell biology from the Rockefeller University in New York, followed by his medical degree from Cornell University and an internal medicine residency at Stanford University.
Frank J. Manion, M.S.
Chief Information Officer
Frank J. Manion, M.S. is the Chief Information/Informatics Officer for the University of Michigan Comprehensive Cancer Center. As part of the Cancer Center's senior leadership team, he oversees strategic planning for and implementation of biomedical informatics and information technology. He also serves as director of the Cancer Informatics Core, which collaborates with Cancer Center members for developing solutions to data integration and analysis problems stemming directly from research initiatives. Mr. Manion joined the Cancer Center in late 2009 from the Fox Chase Cancer Center in Philadelphia, Pennsylvania where he served as Chief Technology Officer and Senior Director for Information Science and Technology. While in that position he was part of the team that developed the first two-centimorgan linkage map of the human genome.
Mr. Manion is active in a number of professional organizations. He is a co-founder of the Biomedical Research Institutions Information Technology Exchange (BRIITE), and a member of the program committee for Cancer Informatics for Cancer Centers (CI4CC). He actively participated on a number of NCI-caBIG workspaces, directed the caBIG "Security Program Development" project, and served on committees for both the AAMC and Internet2. He has served on informatics advisory committees for several NCI-designated Comprehensive Cancer Centers and academic medical centers, including UCSF, Karmanos, Georgetown, and Rockefeller University.
Moshe Talpaz, M.D.
Associate Director of Translational Research and
Alexander J. Trotman Professor of Leukemia research
Internationally known for his role in the development of targeted cancer therapeutics, Dr. Talpaz pioneered the study of interferon in CML, which was the first line therapy for CML until the introduction of STI571 (Gleevec). As a pivotal member of the team that developed Gleevec, Dr. Talpaz was instrumental in bringing to market one of the most effective targeted treatments used to date in cancer care. As a leader in the development of novel therapeutics, Dr. Talpaz has unique experience in the building of Phase I clinical trial programs. In addition to expanding U-M's program in hematologic malignances, he has established a highly successful Phase I therapeutics program at the Cancer Center.
Dr. Talpaz joined U-M in 2006, from M.D. Anderson Cancer Center in Houston, where he was professor of medicine and held the David Bruton Chair for Cancer Research. He has authored or co-authored nearly 400 articles in top national journals and textbooks, and is a member of the American Society of Hematology and the NCCN Chronic Myelogenous Leukemia Guidelines Panel.
Jeremy M.G. Taylor, Ph.D.
Associate Director, Biostatistics Unit
Jeremy M.G. Taylor, Ph.D., Pharmacia Research Professor of Biostatistics in the School of Public Health and of radiation oncology in the Medical School, is associate director for biostatistics of the Cancer Center. As the director of the Biostatistics Unit, Dr. Taylor is responsible for collaborating with research scientists within the Cancer Center on the design of studies and the evaluation and interpretation of scientific data.
Dr. Taylor's own research focuses on developing statistical methods used in cancer research, with specific interest in longitudinal data analysis, surrogate markers, survival analysis, biomarkers and functional genomics. He is a fellow of the American Statistical Association.
Prior to joining the Cancer Center in 1998, Dr. Taylor was professor-in-residence in the Department of Radiation Oncology and the Department of Biostatistics at the University of California Los Angeles. He was the 1996 winner of the Michael Fry Research Award from the Radiation Research Society and the Mortimer Spiegelman Award from the American Public Health Association. Dr. Taylor received his doctoral degree in statistics from the University of California, Berkeley.
Marcy Bohm Waldinger, M.H.S.A.
Chief Administrative Officer
Marcy Bohm Waldinger, M.H.S.A., oversees all aspects of administration including clinical operations, patient support services, cancer registry, business and finance, research administration, marketing communications and development. She was integrally involved in planning the Cancer Center’s nine-story building and is responsible for its clinical and research administration and space management. As a member of the Cancer Center Senior Leadership, Ms. Waldinger functions as a chief operation officer with responsibility to ensure that all aspects of Cancer Center administration effectively supports the programmatic, financial, strategic and management needs of the Center.
Ms. Waldinger is a founding board member of the National Comprehensive Cancer Network (NCCN) and chairs its Best Practices Committee. She is also a member and former board member of the Cancer Center Administrators Forum. She serves as the sole administrator on the Scientific External Advisory Boards of numerous academic cancer centers nationwide, including Duke Cancer Institute, M.D. Anderson Cancer Center, Johns Hopkins, Stanford and Vanderbilt.
Ms. Waldinger joined the Cancer Center in 1992, and has served in an administrative capacity at the University of Michigan Medical Center since 1980.
She received both her undergraduate and graduate degrees from the University of Michigan. Her master's degree in health services administration was obtained from the University of Michigan School of Public Health in 1980.
Gregory T. Wolf, M.D., F.A.C.S.
Director, Specialized Program of Research Excellence in Head and Neck Cancer
Gregory T. Wolf, M.D., professor and chair of Otolaryngology/Head and Neck Surgery at the University of Michigan, serves as the Cancer Center's Associate Director for the Specialized Program of Research Excellence (SPORE) grant in head and neck cancer. As the principal investigator of the $12 million National Cancer Institute grant, Dr. Wolf is responsible for overseeing the administrative and scientific direction of this multidisciplinary, translational research program examining the molecular basis of head and neck cancer.
Dr. Wolf has been principal investigator and study chairman of several national multi-institutional clinical trials which are investigating the use of induction chemotherapy for organ preservation in head and neck cancer. His main research interests have been in tumor immunology, immunotherapy and cell biology, and his clinical trial research has included studies of immunotherapy and chemotherapy regimens. Dr. Wolf received national recognition as study chairman of two large prospective randomized trials that have provided the foundation for changing the standard therapy for patients with advanced laryngeal cancers.
Prior to joining the faculty of the University of Michigan in 1980, Dr. Wolf completed a two-year immunology fellowship at the National Institutes of Health. He received his medical degree from the University of Michigan followed by postgraduate training in otolaryngology and general surgery at the State University of New York, Upstate Medical Center in Syracuse, and Georgetown University.
Associate Director for Cancer Prevention and Control